Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates

L J Marnett, L J Marnett

Abstract

Prostaglandin-H synthase is unique among enzymes of the plant and animal kingdom in its ability to biosynthesize and metabolize hydroperoxides. Its cyclooxygenase activity oxygenates polyunsaturated fatty acids to hydroperoxy endoperoxides, and its peroxidase activity reduces the hydroperoxy group to hydroxy groups. Higher oxidation states of the peroxidase oxidize reducing substrates to electron-deficient derivatives that react with macromolecular nucleophiles. In the case of aromatic amines, the electron-deficient derivatives are mutagenic to bacterial and mammalian cells. beta-Dicarbonyl compounds and retinoic acid are oxidized to carbon-centered radicals that react with O2 to form peroxyl free radicals. Peroxyl radicals are the most stable oxy radicals and are able to diffuse some distance from the site of their generation. Peroxyl radicals are also formed during lipid peroxidation and in the reaction of polyunsaturated fatty acid hydroperoxides with metal complexes and metalloproteins. Peroxyl radicals epoxidize isolated doubled bonds of compounds such as 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene (BP-7,8-diol); 3,4-dihydroxy-3,4-dihydrobenzo(a)anthracene; and aflatoxin B1. The epoxide products represent the ultimate carcinogenic forms of the respective compounds. Techniques for quantitating the extent of peroxidase dependent or peroxyl radical-dependent metabolism in vivo make use of differences in the structure or stereochemistry of reactive intermediates formed by peroxidases relative to cytochromes P-450. Differences in the relative amounts of hydrolysis products and DNA adducts derived from anti- and syn-dihydrodiolepoxides following application of BP-7,8-diol to mouse skin in vivo indicate peroxyl radicals play a significant role in metabolism of BP-7,8-diol in uninduced animals.

References

    1. Cancer Res. 1989 Apr 1;49(7):1732-7
    1. J Biochem Toxicol. 1989 Summer;4(2):111-7
    1. Toxicol Appl Pharmacol. 1989 Mar 1;97(3):406-14
    1. J Biol Chem. 1967 Nov 25;242(22):5344-54
    1. Biochim Biophys Acta. 1968 Oct 22;164(2):426-9
    1. Biochim Biophys Acta. 1968 Oct 22;164(2):430-2
    1. Eur J Cancer. 1972 Dec;8(6):689-93
    1. Biochim Biophys Acta. 1973 Dec 20;326(3):448-61
    1. Biochem Biophys Res Commun. 1978 May 15;82(1):210-6
    1. J Biol Chem. 1978 Jul 25;253(14):5061-8
    1. J Biol Chem. 1979 Feb 10;254(3):829-36
    1. FEBS Lett. 1979 Oct 1;106(1):13-6
    1. FEBS Lett. 1979 Oct 1;106(1):17-20
    1. J Biol Chem. 1980 Jan 25;255(2):323-6
    1. J Biol Chem. 1980 May 25;255(10):4872-5
    1. Adv Prostaglandin Thromboxane Res. 1980;6:149-51
    1. Annu Rev Physiol. 1986;48:657-67
    1. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7499-502
    1. Biochem Biophys Res Commun. 1986 Oct 15;140(1):181-7
    1. Carcinogenesis. 1986 Dec;7(12):1957-63
    1. Carcinogenesis. 1987 Mar;8(3):387-90
    1. Carcinogenesis. 1987 Apr;8(4):541-5
    1. J Biol Chem. 1987 May 5;262(13):6266-79
    1. Cancer Res. 1987 Oct 15;47(20):5354-60
    1. Carcinogenesis. 1987 Oct;8(10):1365-73
    1. J Biol Chem. 1987 Oct 15;262(29):14119-33
    1. Proc Natl Acad Sci U S A. 1974 Feb;71(2):345-9
    1. J Biol Chem. 1975 Nov 10;250(21):8510-7
    1. J Biol Chem. 1976 May 10;251(9):2629-36
    1. J Biol Chem. 1976 Sep 25;251(18):5575-9
    1. Biochim Biophys Acta. 1977 May 25;487(2):315-31
    1. Cancer Res. 1978 Mar;38(3):793-801
    1. Chem Biol Interact. 1981 Jan;33(2-3):239-52
    1. J Biol Chem. 1981 Jul 25;256(14):7352-61
    1. J Biol Chem. 1981 Oct 10;256(19):10018-22
    1. Methods Enzymol. 1982;86:55-60
    1. Methods Enzymol. 1982;86:60-8
    1. Cancer Res. 1983 Feb;43(2):476-80
    1. Cancer Res. 1983 Mar;43(3):992-6
    1. Carcinogenesis. 1983;4(3):331-3
    1. J Biol Chem. 1983 May 10;258(9):5922-6
    1. Science. 1983 Jul 1;221(4605):77-9
    1. Biochemistry. 1983 Sep 27;22(20):4672-5
    1. FEBS Lett. 1984 Jan 9;165(2):293-6
    1. J Biol Chem. 1984 May 10;259(9):5591-5
    1. J Biol Chem. 1984 May 25;259(10):6358-63
    1. Methods Enzymol. 1984;105:347-52
    1. Eur J Biochem. 1988 Jan 15;171(1-2):313-20
    1. J Biol Chem. 1988 Feb 25;263(6):3022-8
    1. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1412-6
    1. J Biol Chem. 1988 Mar 15;263(8):3550-3
    1. FEBS Lett. 1988 Apr 25;231(2):347-51
    1. J Biol Chem. 1988 Jun 5;263(16):7846-54
    1. Mol Pharmacol. 1988 Aug;34(2):186-93
    1. J Biol Chem. 1988 Nov 15;263(32):16532-5
    1. Carcinogenesis. 1984 Jul;5(7):955-60
    1. Mol Pharmacol. 1984 Sep;26(2):328-35
    1. Carcinogenesis. 1985 Jan;6(1):155-8
    1. J Biol Chem. 1985 Feb 10;260(3):1601-7
    1. J Lipid Res. 1985 Jan;26(1):54-61
    1. Cancer Res. 1985 Apr;45(4):1680-6
    1. Eur J Biochem. 1985 Mar 15;147(3):569-74
    1. J Biol Chem. 1985 May 10;260(9):5351-7
    1. J Biol Chem. 1985 May 10;260(9):5358-65
    1. Carcinogenesis. 1985 Aug;6(8):1227-9
    1. J Biol Chem. 1985 Dec 5;260(28):14894-6
    1. Anal Biochem. 1985 Oct;150(1):91-6
    1. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2771-5
    1. J Biol Chem. 1988 Dec 15;263(35):19043-7
    1. Biochem Biophys Res Commun. 1988 Dec 30;157(3):1159-63
    1. Carcinogenesis. 1989 Jan;10(1):91-6
    1. Proc Natl Acad Sci U S A. 1989 Mar;86(5):1657-61

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren